Sam Facelli

Note: the AssemblyAI diarization renders this analyst's name as "Sam Facelli" / "Sam Faselli"; the real name is Sam Fazeli (both recorded as aliases). The page basename stays sam-facelli for link stability.

One-line summary: Senior pharma analyst and Biotech Hangout roundtable regular; covers oncology/EGFR and cardiometabolic pipelines, deal analysis (AZN/Dizal, Erasca), and the US/China biotech-innovation balance.

What they're known for

A senior biotech/pharma equity analyst; a fixture on the Biotech Hangout roundtable where he handles much of the deal- and data-level analysis (EGFR-space competitive reads, financing signals, mechanism trade-offs).

Why they matter to stock-market

Fazeli's reads tend to be the panel's most granular on competitive positioning and deal quality — e.g. that AstraZeneca is "the ideal partner" for Dizal's sunvozertinib given its EGFR franchise, that Erasca's upsized $500M raise is a conviction signal in a weak tape, and (from earlier episodes) that Chinese innovation is at parity in chemistry/materials science — which nuances the offshoring thesis toward "manufacturing security, not innovation restriction." He also flags the AZN oral-obesity + oral-PCSK9 combination ambition.

Said

Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.

• On us-biotech-strategic-technology-offshoring:

  "There's no reason why Chinese innovation is going to be any worse. They lead already in material science and chemistry by far in terms of share of new ideas and new ideas generation." — 2026-06-09-podcast-biotech-hangout-episode-185-june-5-2026 (2026-06-09)

• On eli-lilly:

  "they seem to be going in every possible area of pharma now... this is the third PNS type disease that's outside of... neurodegeneration. And I think it speaks volumes to how they're thinking about the future which will inevitably include some kind of plateau or pressure on their obesity franchise." — 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 (2026-07-17)

• On astrazeneca:

  "the data stacks up and the side effect profile looks easier to manage. And I think astra is the ideal partner here to be selling this given that they have the broader EGFR space." — 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 (2026-07-17)

• On erasca:

  "the 500 million raise, which was upsized to about 600 something... in a market that was looking a bit dodgy... sounds like a sign of somebody believes in this. With the data improved relative to an addition of four more patients and a month more of follow up." — 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 (2026-07-17)

• On oral-pcsk9-class-disruption:

  "Astra's masters ambitions is to do a combination with their oral obesity drug. That's what they've talked about. Whether that's a fixed dose combination or not, I don't know." — 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 (2026-07-17)

Sources

• 2026-06-09-podcast-biotech-hangout-episode-185-june-5-2026
• 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026

Related

• us-biotech-strategic-technology-offshoring · oral-pcsk9-class-disruption
• astrazeneca · erasca · eli-lilly
• matt-gline · john-maraganore · yaron-werber — Biotech Hangout co-panelists